2015
DOI: 10.1007/s00104-014-2971-z
|View full text |Cite
|
Sign up to set email alerts
|

Salvage-Chirurgie bei Ösophaguskarzinomen

Abstract: Salvage esophagectomy is now an additional treatment option after definitive radio(chemo)therapy in patients with esophageal cancer. In preselected patients with tumor recurrence, progression or with a strong wish for surgical therapy, salvage surgery should be discussed in interdisciplinary tumor boards after exclusion of distant metastases.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 39 publications
0
3
0
Order By: Relevance
“…Similar as other aggressive treatment strategies, i.e. salvage surgery for esophageal cancer after definitive radiotherapy (29), this aggressive surgical approach needs to be evaluated. Our data with a median survival of 20 months for all included patients with metastatic disease encourages this aggressive multimodal treatment strategy.…”
Section: Discussionmentioning
confidence: 99%
“…Similar as other aggressive treatment strategies, i.e. salvage surgery for esophageal cancer after definitive radiotherapy (29), this aggressive surgical approach needs to be evaluated. Our data with a median survival of 20 months for all included patients with metastatic disease encourages this aggressive multimodal treatment strategy.…”
Section: Discussionmentioning
confidence: 99%
“…The database search retrieved 530 publications, including 19 targeted studies, from 2002 to 2022 which met the inclusion criteria and were included in the review (Supplementary Data Table S1-3). [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] Across the 19 studies, a total of 25 782 patients were included: 23555 in the planned oesophagectomy group and 2227 in the salvage oesophagectomy group. There were eight studies from Japan, six studies from the USA and one each from Australia, Taiwan, Germany, Belgium and 'Europe'.…”
Section: Study Characteristicsmentioning
confidence: 99%
“…28 All studies were retrospective in design and all but one study from 'Europe' 28 derived data from a hospital-based registry. Nine studies 19,20,22,23,[31][32][33][34][35] included patients with only SCC, two studies 25,30 included patients with only adenocarcinoma and eight studies 18,21,24,[26][27][28][29]36 included patients with both subtypes.…”
Section: Study Characteristicsmentioning
confidence: 99%